Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 16,841 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Human Immunodeficiency Virus
Interventions: Social Network, Brief HIV Prevention Counseling; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 16 Years and older · Male only
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Cleveland, Ohio • Milwaukee, Wisconsin

Conditions: Polycystic Ovary Syndrome (PCOS)
Interventions: Flutamide, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Autism, Autism Spectrum Disorder, Autistic Disorder, Autism, Akinetic, Autism; Atypical, Autism; Psychopathy, Autism Fragile Syndrome X, Autism With High Cognitive Abilities, Autism-Related Speech Delay, Autism, Susceptibility to, 6, Autism Spectrum Disorder High-Functioning, Autistic Thinking, Autism, Susceptibility to, X-Linked 6, Autistic Behavior
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 6 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Legg Calve Perthes Disease
Interventions: Osteotomy + Long Term Non-Weight Bearing, Osteotomy + Short Term Non-Weight Bearing, Nonoperative Observation, Multiple Epiphyseal Drilling; Procedure
Lead sponsor: Texas Scottish Rite Hospital for Children; Other
Eligibility: 1 Year to 18 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2032
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more

Conditions: Williams Syndrome
Interventions: Response Inhibition Training; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 10 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Hydroxyurea, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 34
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 24 more

Conditions: Genitourinary Syndrome of Menopause
Interventions: CO2 laser, OCT; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Irvine, California

Conditions: Obstructive Sleep Apnea
Interventions: High-resolution pharyngeal manometry catheter; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mitochondrial Disorders, Mitochondrial Disease, Melas, Kearns Sayer, NARP, MNGIE, LHON, Mitochondrial Depletion Syndrome, Leigh's Disease
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 6,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Durvalumab, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Positron Emission Tomography (PET), Computed Tomography; Drug · Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metabolic Syndrome, Breast Cancer Prevention, Physical Activity
Interventions: Enhanced physical activity monitor which is Fitbit watch with mobile App, Bollywood-style group dance, PAMDance; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Sugar Grove, Illinois

Conditions: Sepsis
Interventions: Epic Sepsis Model Version - 1, Epic Sepsis Model Version - 2, Emory Sepsis Model; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 7
States / cities: Atlanta, Georgia • Decatur, Georgia • Johns Creek, Georgia + 1 more

Conditions: Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions: Ultomiris; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Progeria, Hutchinson-Gilford Syndrome
Interventions: Lonafarnib, Zoledronic Acid, Pravastatin; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
Interventions: imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis; Drug · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 21 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more

Conditions: Obstructive Sleep Apnea
Interventions: Automated Management (AM); Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Fontana, California • Kansas City, Kansas • Danville, Pennsylvania + 1 more

Conditions: HIV Infections
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2003
U.S. locations: 17
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Eculizumab; Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: HIV Infections, Anti-Infective Agents
Interventions: No intervention (not applicable); Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Moral Injury Syndrome
Interventions: Building Spiritual Strength, Present Centered Group Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Little Rock, Arkansas • Decatur, Georgia • Augusta, Maine + 2 more

Conditions: HIV Infections
Interventions: Ad26.ENVA.01 (rAd26), Placebo Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Metabolic Syndrome, Dyslipidemia
Interventions: Not listed
Lead sponsor: Interleukin Genetics, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 824 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 5 Years to 100 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Increasing PrEP Use in High-Risk Social Networks of African-American MSM in Underserved Low-Risk Cities

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Autism

Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease

Response Inhibition Training for Children With Williams Syndrome

Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy

Pharyngeal Anatomy In Obstructive Sleep Apnea With HRM

Tissue Sample Study for Mitochondrial Disorders

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women

Comparison of Sepsis Prediction Algorithms

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Enhancing PAP Adherence Among Spanish-speaking Hispanic Adults With OSA

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

Acceptability Study of Vaginal Films for HIV Prevention

Implementation of Innovative Treatment for Moral Injury Syndrome: A Hybrid Type 2 Study

Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults

Association of Genes to Resistance to Weight Loss in Obese Patients

Natural History of Bronchiectasis